- Home
- PBM vs SONN Comparison
PBM vs SONN Comparison
Compare PBM & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBM
- SONN
- Stock Information
- Founded
- PBM 1994
- SONN N/A
- Country
- PBM Canada
- SONN United States
- Employees
- PBM N/A
- SONN N/A
- Industry
- PBM
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- PBM
- SONN Health Care
- Exchange
- PBM NYSE
- SONN Nasdaq
- Market Cap
- PBM 3.5M
- SONN 3.8M
- IPO Year
- PBM N/A
- SONN N/A
- Fundamental
- Price
- PBM $7.03
- SONN $3.26
- Analyst Decision
- PBM
- SONN Strong Buy
- Analyst Count
- PBM 0
- SONN 1
- Target Price
- PBM N/A
- SONN $20.00
- AVG Volume (30 Days)
- PBM 86.1K
- SONN 11.6M
- Earning Date
- PBM 08-05-2025
- SONN 08-13-2025
- Dividend Yield
- PBM N/A
- SONN N/A
- EPS Growth
- PBM N/A
- SONN N/A
- EPS
- PBM 41.77
- SONN N/A
- Revenue
- PBM N/A
- SONN $1,000,000.00
- Revenue This Year
- PBM N/A
- SONN $5,376.22
- Revenue Next Year
- PBM N/A
- SONN N/A
- P/E Ratio
- PBM $0.22
- SONN N/A
- Revenue Growth
- PBM N/A
- SONN 978.39
- 52 Week Low
- PBM $2.93
- SONN $1.08
- 52 Week High
- PBM $402.00
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- PBM 52.87
- SONN 43.00
- Support Level
- PBM $5.05
- SONN $3.83
- Resistance Level
- PBM $11.99
- SONN $4.38
- Average True Range (ATR)
- PBM 1.29
- SONN 1.92
- MACD
- PBM 0.34
- SONN -0.50
- Stochastic Oscillator
- PBM 30.67
- SONN 0.99
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.